{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:37:50Z","timestamp":1773740270147,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologe"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00117-019-00632-x","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T17:04:57Z","timestamp":1576170297000},"page":"28-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Interventional therapy in malignant conditions of the prostate","Interventionelle Therapie maligner Erkrankungen der Prostata"],"prefix":"10.1007","volume":"59","author":[{"given":"Attila","family":"Kov\u00e1cs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pinkawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"key":"632_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Fitzmaurice\u00a0C, Allen\u00a0C, Barber\u00a0RM et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3:524\u2013548. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5688","journal-title":"JAMA Oncol"},{"key":"632_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel\u00a0RL, Miller\u00a0KD, Jemal\u00a0A (2018) Cancer statistics. CA Cancer J Clin 68:7\u201330. https:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"key":"632_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/bju.13524","volume":"118","author":"K Pereira","year":"2016","unstructured":"Pereira\u00a0K, Halpern\u00a0JA, McClure\u00a0TD et\u00a0al (2016) Role of prostate artery embolization in the management of refractory haematuria of prostatic origin. BJU Int 118:359\u2013365. https:\/\/doi.org\/10.1111\/bju.13524","journal-title":"BJU Int"},{"key":"632_CR4","first-page":"99","volume":"16","author":"W Bischoff","year":"1977","unstructured":"Bischoff\u00a0W, Goerttler\u00a0U (1977) Successful intra-arterial embolization of bleeding carcinoma of the prostate (author\u2019s transl). Urologe\u00a0A 16:99\u2013102","journal-title":"Urologe A"},{"key":"632_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jvir.2017.10.013","volume":"29","author":"J Pisco","year":"2018","unstructured":"Pisco\u00a0J, Bilhim\u00a0T, Costa\u00a0NV et al (2018) Safety and efficacy of prostatic artery chemoembolization for prostate cancer-initial experience. J\u00a0Vasc Interv Radiol 29:298\u2013305. https:\/\/doi.org\/10.1016\/j.jvir.2017.10.013","journal-title":"J Vasc Interv Radiol"},{"key":"632_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jvir.2013.11.003","volume":"25","author":"J Golzarian","year":"2014","unstructured":"Golzarian\u00a0J, Antunes\u00a0AA, Bilhim\u00a0T et\u00a0al (2014) Prostatic artery embolization to treat lower urinary tract symptoms related to benign prostatic hyperplasia and bleeding in patients with prostate cancer: proceedings from a\u00a0multidisciplinary research consensus panel. J\u00a0Vasc Interv Radiol 25:665\u2013674. https:\/\/doi.org\/10.1016\/j.jvir.2013.11.003","journal-title":"J Vasc Interv Radiol"},{"issue":"Suppl 8","key":"632_CR7","first-page":"S10","volume":"6","author":"JW Moul","year":"2004","unstructured":"Moul\u00a0JW (2004) The evolving definition of advanced prostate cancer. Rev Urol 6(Suppl 8):S10\u2013S17","journal-title":"Rev Urol"},{"key":"632_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00120-019-0900-y","volume":"58","author":"J Lakes","year":"2019","unstructured":"Lakes\u00a0J, Arsov\u00a0C (2019) PSA screening and molecular markers. Urologe\u00a0A 58:486\u2013493. https:\/\/doi.org\/10.1007\/s00120-019-0900-y","journal-title":"Urologe A"},{"key":"632_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clon.2013.05.002","volume":"25","author":"V Kasivisvanathan","year":"2013","unstructured":"Kasivisvanathan\u00a0V, Emberton\u00a0M, Ahmed\u00a0HU (2013) Focal therapy for prostate cancer: rationale and treatment opportunities. Clin Oncol 25:461\u2013473. https:\/\/doi.org\/10.1016\/j.clon.2013.05.002","journal-title":"Clin Oncol"},{"key":"632_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.7326\/0003-4819-148-6-200803180-00209","volume":"148","author":"TJ Wilt","year":"2008","unstructured":"Wilt\u00a0TJ, MacDonald\u00a0R, Rutks\u00a0I et\u00a0al (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148:435\u2013448. https:\/\/doi.org\/10.7326\/0003-4819-148-6-200803180-00209","journal-title":"Ann Intern Med"},{"key":"632_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet\u00a0N, Bellmunt\u00a0J, Bolla\u00a0M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618\u2013629. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003","journal-title":"Eur Urol"},{"key":"632_CR12","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1056\/NEJMcibr0905562","volume":"361","author":"HU Ahmed","year":"2009","unstructured":"Ahmed\u00a0HU (2009) The index lesion and the origin of prostate cancer. N\u00a0Engl J Med 361:1704\u20131706. https:\/\/doi.org\/10.1056\/NEJMcibr0905562","journal-title":"N Engl J Med"},{"key":"632_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.eururo.2015.01.030","volume":"68","author":"HU Ahmed","year":"2015","unstructured":"Ahmed\u00a0HU, Dickinson\u00a0L, Charman\u00a0S et\u00a0al (2015) Focal ablation targeted to the index lesion in multifocal Localised prostate cancer: a\u00a0prospective development study. Eur Urol 68:927\u2013936. https:\/\/doi.org\/10.1016\/j.eururo.2015.01.030","journal-title":"Eur Urol"},{"key":"632_CR14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.eururo.2014.09.018","volume":"67","author":"IA Donaldson","year":"2015","unstructured":"Donaldson\u00a0IA, Alonzi\u00a0R, Barratt\u00a0D et\u00a0al (2015) Focal therapy: patients, interventions, and outcomes\u2014a report from a\u00a0consensus meeting. Eur Urol 67:771\u2013777. https:\/\/doi.org\/10.1016\/j.eururo.2014.09.018","journal-title":"Eur Urol"},{"key":"632_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00606","author":"JE Bekelman","year":"2018","unstructured":"Bekelman\u00a0JE, Rumble\u00a0RB, Chen\u00a0RC et\u00a0al (2018) Clinically localized prostate cancer: aSCO clinical practice guideline endorsement of an American Urological Association\/American Society for Radiation Oncology\/Society of Urologic Oncology guideline. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/jco.18.00606","journal-title":"J Clin Oncol"},{"key":"632_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00120-017-0488-z","volume":"56","author":"R Ganzer","year":"2017","unstructured":"Ganzer\u00a0R, Franiel\u00a0T, Kollermann\u00a0J et\u00a0al (2017) Focal therapy of prostate cancer. Urologe\u00a0A 56:1335\u20131346. https:\/\/doi.org\/10.1007\/s00120-017-0488-z","journal-title":"Urologe A"},{"key":"632_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.23736\/s0393-2249.18.03094-1","volume":"70","author":"E Linares-Espinos","year":"2018","unstructured":"Linares-Espinos\u00a0E, Carneiro\u00a0A, Martinez-Salamanca\u00a0JI et al (2018) New technologies and techniques for prostate cancer focal therapy. Minerva Urol Nefrol 70:252\u2013263. https:\/\/doi.org\/10.23736\/s0393-2249.18.03094-1","journal-title":"Minerva Urol Nefrol"},{"key":"632_CR18","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.juro.2007.08.072","volume":"178","author":"SE Eggener","year":"2007","unstructured":"Eggener\u00a0SE, Scardino\u00a0PT, Carroll\u00a0PR et\u00a0al (2007) Focal therapy for localized prostate cancer: a\u00a0critical appraisal of rationale and modalities. J\u00a0Urol 178:2260\u20132267. https:\/\/doi.org\/10.1016\/j.juro.2007.08.072","journal-title":"J Urol"},{"key":"632_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1089\/end.2009.0596","volume":"24","author":"J de la Rosette","year":"2010","unstructured":"de la Rosette\u00a0J, Ahmed\u00a0H, Barentsz\u00a0J et al (2010) Focal therapy in prostate cancer-report from a\u00a0consensus panel. J\u00a0Endourol 24:775\u2013780. https:\/\/doi.org\/10.1089\/end.2009.0596","journal-title":"J Endourol"},{"key":"632_CR20","doi-asserted-by":"publisher","first-page":"e006382","DOI":"10.1136\/bmjopen-2014-006382","volume":"4","author":"W van den Bos","year":"2014","unstructured":"van den Bos\u00a0W, de Bruin\u00a0DM, Muller\u00a0BG et\u00a0al (2014) The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a\u00a0multicentre prospective human in vivo pilot study protocol. BMJ Open 4:e6382. https:\/\/doi.org\/10.1136\/bmjopen-2014-006382","journal-title":"BMJ Open"},{"key":"632_CR21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00120-019-0901-x","volume":"58","author":"D Bonekamp","year":"2019","unstructured":"Bonekamp\u00a0D, Salomon\u00a0G (2019) Imaging for initial diagnosis of localized prostate cancer. Urologe\u00a0A 58:494\u2013503. https:\/\/doi.org\/10.1007\/s00120-019-0901-x","journal-title":"Urologe A"},{"key":"632_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4111\/icu.2019.60.1.4","volume":"60","author":"S Shoji","year":"2019","unstructured":"Shoji\u00a0S (2019) Magnetic resonance imaging-transrectal ultrasound fusion image-guided prostate biopsy: current status of the cancer detection and the prospects of tailor-made medicine of the prostate cancer. Investig Clin Urol 60:4\u201313. https:\/\/doi.org\/10.4111\/icu.2019.60.1.4","journal-title":"Investig Clin Urol"},{"key":"632_CR23","doi-asserted-by":"publisher","first-page":"e198427","DOI":"10.1001\/jamanetworkopen.2019.8427","volume":"2","author":"MMC Elwenspoek","year":"2019","unstructured":"Elwenspoek\u00a0MMC, Sheppard\u00a0AL, McInnes\u00a0MDF et al (2019) Comparison of multiparametric magnetic resonance imaging and targeted biopsy with systematic biopsy alone for the diagnosis of prostate cancer: a systematic review and meta-analysis. JAMA Netw Open 2:e198427. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.8427","journal-title":"JAMA Netw Open"},{"key":"632_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.eururo.2018.01.001","volume":"74","author":"HG van der Poel","year":"2018","unstructured":"van der Poel\u00a0HG, van den Bergh\u00a0RCN, Briers\u00a0E et\u00a0al (2018) Focal therapy in primary Localised prostate cancer: the European Association of Urology position in 2018. Eur Urol 74:84\u201391. https:\/\/doi.org\/10.1016\/j.eururo.2018.01.001","journal-title":"Eur Urol"},{"key":"632_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3348\/kjr.2017.18.4.597","volume":"18","author":"JJ Futterer","year":"2017","unstructured":"Futterer\u00a0JJ (2017) Multiparametric MRI in the detection of clinically significant prostate cancer. Korean J Radiol 18:597\u2013606. https:\/\/doi.org\/10.3348\/kjr.2017.18.4.597","journal-title":"Korean J Radiol"},{"key":"632_CR26","doi-asserted-by":"publisher","first-page":"588","DOI":"10.23736\/s0393-2249.18.03126-0","volume":"70","author":"F Hoffkes","year":"2018","unstructured":"Hoffkes\u00a0F, Arthanareeswaran\u00a0VK, Stolzenburg\u00a0JU et al (2018) Rate of misclassification in patients undergoing radical prostatectomy but fulfilling active surveillance criteria according to the European Association of Urology guidelines on prostate cancer: a\u00a0high-volume center experience. Minerva Urol Nefrol 70:588\u2013593. https:\/\/doi.org\/10.23736\/s0393-2249.18.03126-0","journal-title":"Minerva Urol Nefrol"},{"key":"632_CR27","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/j.juro.2009.07.024","volume":"182","author":"AS Duffield","year":"2009","unstructured":"Duffield\u00a0AS, Lee\u00a0TK, Miyamoto\u00a0H et\u00a0al (2009) Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J\u00a0Urol 182:2274\u20132278. https:\/\/doi.org\/10.1016\/j.juro.2009.07.024","journal-title":"J Urol"},{"key":"632_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMc1807507","volume":"379","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan\u00a0V, Emberton\u00a0M, Moore\u00a0CM (2018) MRI-targeted biopsy for prostate-cancer diagnosis. N\u00a0Engl J Med 379:589\u2013590. https:\/\/doi.org\/10.1056\/NEJMc1807507","journal-title":"N Engl J Med"},{"key":"632_CR29","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan\u00a0V, Rannikko\u00a0AS, Borghi\u00a0M et al (2018) MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N\u00a0Engl J Med 378:1767\u20131777. https:\/\/doi.org\/10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"key":"632_CR30","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamaoncol.2017.5667","volume":"4","author":"S Mehralivand","year":"2018","unstructured":"Mehralivand\u00a0S, Shih\u00a0JH, Rais-Bahrami\u00a0S et al (2018) A magnetic resonance imaging-based prediction model for prostate biopsy risk stratification. JAMA Oncol 4:678\u2013685. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5667","journal-title":"JAMA Oncol"},{"key":"632_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2014.17942","volume":"313","author":"MM Siddiqui","year":"2015","unstructured":"Siddiqui\u00a0MM, Rais-Bahrami\u00a0S, Turkbey\u00a0B et al (2015) Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313:390\u2013397. https:\/\/doi.org\/10.1001\/jama.2014.17942","journal-title":"JAMA"},{"key":"632_CR32","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.juro.2015.01.088","volume":"193","author":"MM Siddiqui","year":"2015","unstructured":"Siddiqui\u00a0MM, Truong\u00a0H, Rais-Bahrami\u00a0S et al (2015) Clinical implications of a\u00a0multiparametric magnetic resonance imaging based nomogram applied to prostate cancer active surveillance. J\u00a0Urol 193:1943\u20131949. https:\/\/doi.org\/10.1016\/j.juro.2015.01.088","journal-title":"J Urol"},{"key":"632_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/mou.0000000000000245","volume":"26","author":"A Grey","year":"2016","unstructured":"Grey\u00a0A, Ahmed\u00a0HU (2016) Multiparametric ultrasound in the diagnosis of prostate cancer. Curr Opin Urol 26:114\u2013119. https:\/\/doi.org\/10.1097\/mou.0000000000000245","journal-title":"Curr Opin Urol"},{"key":"632_CR34","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00120-019-0862-0","volume":"58","author":"M Schostak","year":"2019","unstructured":"Schostak\u00a0M (2019) Focal therapy for prostate cancer. Urologe\u00a0A 58:518\u2013523. https:\/\/doi.org\/10.1007\/s00120-019-0862-0","journal-title":"Urologe A"},{"key":"632_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41391-018-0042-0","volume":"21","author":"R Ganzer","year":"2018","unstructured":"Ganzer\u00a0R, Arthanareeswaran\u00a0VKA, Ahmed\u00a0HU et al (2018) Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement. Prostate Cancer Prostatic Dis 21:175\u2013186. https:\/\/doi.org\/10.1038\/s41391-018-0042-0","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"632_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.radonc.2013.08.043","volume":"110","author":"PJ Hoskin","year":"2014","unstructured":"Hoskin\u00a0PJ, Rojas\u00a0AM, Ostler\u00a0PJ et\u00a0al (2014) Dosimetric predictors of biochemical control of prostate cancer in patients randomised to external beam radiotherapy with a\u00a0boost of high dose rate brachytherapy. Radiother Oncol 110:110\u2013113. https:\/\/doi.org\/10.1016\/j.radonc.2013.08.043","journal-title":"Radiother Oncol"},{"key":"632_CR37","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.clon.2013.04.009","volume":"25","author":"GC Morton","year":"2013","unstructured":"Morton\u00a0GC, Hoskin\u00a0PJ (2013) Brachytherapy: current status and future strategies\u2014can high dose rate replace low dose rate and external beam radiotherapy? Clin Oncol 25:474\u2013482. https:\/\/doi.org\/10.1016\/j.clon.2013.04.009","journal-title":"Clin Oncol"},{"key":"632_CR38","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1590\/s1677-5538.Ibju.2016.0664","volume":"43","author":"C Redondo","year":"2017","unstructured":"Redondo\u00a0C, Srougi\u00a0V, da Costa\u00a0JB et\u00a0al (2017) Focal cryotherapy: step by step technique description. Int Braz J Urol 43:995\u2013996. https:\/\/doi.org\/10.1590\/s1677-5538.Ibju.2016.0664","journal-title":"Int Braz J Urol"},{"key":"632_CR39","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1089\/end.2014.0881","volume":"29","author":"MH Mendez","year":"2015","unstructured":"Mendez\u00a0MH, Passoni\u00a0NM, Pow-Sang\u00a0J et al (2015) Comparison of outcomes between preoperatively potent men treated with focal versus whole gland cryotherapy in a\u00a0matched population. J\u00a0Endourol 29:1193\u20131198. https:\/\/doi.org\/10.1089\/end.2014.0881","journal-title":"J Endourol"},{"key":"632_CR40","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1089\/end.2016.0830","volume":"31","author":"KJ Tay","year":"2017","unstructured":"Tay\u00a0KJ, Polascik\u00a0TJ, Elshafei\u00a0A et al (2017) Propensity score-matched comparison of partial to whole-gland cryotherapy for intermediate-risk prostate cancer: an analysis of the cryo on-line data registry data. J\u00a0Endourol 31:564\u2013571. https:\/\/doi.org\/10.1089\/end.2016.0830","journal-title":"J Endourol"},{"key":"632_CR41","doi-asserted-by":"publisher","first-page":"150.e151","DOI":"10.1016\/j.urolonc.2016.11.008","volume":"35","author":"M Valerio","year":"2017","unstructured":"Valerio\u00a0M, Shah\u00a0TT, Shah\u00a0P et al (2017) Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study. Urol Oncol 35:150.e151\u2013150.e157. https:\/\/doi.org\/10.1016\/j.urolonc.2016.11.008","journal-title":"Urol Oncol"},{"key":"632_CR42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eururo.2016.09.039","volume":"71","author":"P Rischmann","year":"2017","unstructured":"Rischmann\u00a0P, Gelet\u00a0A, Riche\u00a0B et\u00a0al (2017) Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients. Eur Urol 71:267\u2013273. https:\/\/doi.org\/10.1016\/j.eururo.2016.09.039","journal-title":"Eur Urol"},{"key":"632_CR43","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1148\/radiol.2017161650","volume":"285","author":"KJ Tay","year":"2017","unstructured":"Tay\u00a0KJ, Cheng\u00a0CWS, Lau\u00a0WKO et al (2017) Focal therapy for prostate cancer with in-bore MR-guided focused ultrasound: two-year follow-up of a\u00a0phase I trial-complications and functional outcomes. Radiology 285:620\u2013628. https:\/\/doi.org\/10.1148\/radiol.2017161650","journal-title":"Radiology"},{"key":"632_CR44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00345-016-1924-1","volume":"35","author":"JGR Bomers","year":"2017","unstructured":"Bomers\u00a0JGR, Cornel\u00a0EB, Futterer\u00a0JJ et al (2017) MRI-guided focal laser ablation for prostate cancer followed by radical prostatectomy: correlation of treatment effects with imaging. World J Urol 35:703\u2013711. https:\/\/doi.org\/10.1007\/s00345-016-1924-1","journal-title":"World J Urol"},{"key":"632_CR45","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/bju.12265","volume":"112","author":"AR Azzouzi","year":"2013","unstructured":"Azzouzi\u00a0AR, Barret\u00a0E, Moore\u00a0CM et al (2013) TOOKAD((R)) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int 112:766\u2013774. https:\/\/doi.org\/10.1111\/bju.12265","journal-title":"BJU Int"},{"key":"632_CR46","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.2147\/ott.S88086","volume":"9","author":"PG Wagstaff","year":"2016","unstructured":"Wagstaff\u00a0PG, Buijs\u00a0M, van den Bos\u00a0W et\u00a0al (2016) Irreversible electroporation: state of the art. Onco Targets Ther 9:2437\u20132446. https:\/\/doi.org\/10.2147\/ott.S88086","journal-title":"Onco Targets Ther"},{"key":"632_CR47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00345-015-1661-x","volume":"34","author":"W van den Bos","year":"2016","unstructured":"van den Bos\u00a0W, de Bruin\u00a0DM, Jurhill\u00a0RR et\u00a0al (2016) The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients. World J Urol 34:657\u2013664. https:\/\/doi.org\/10.1007\/s00345-015-1661-x","journal-title":"World J Urol"},{"key":"632_CR48","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1007\/s00330-015-4042-3","volume":"26","author":"W van den Bos","year":"2016","unstructured":"van den Bos\u00a0W, de Bruin\u00a0DM, van Randen\u00a0A et al (2016) MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a\u00a0phase I\u2011II study in patients undergoing IRE followed by radical prostatectomy. Eur Radiol 26:2252\u20132260. https:\/\/doi.org\/10.1007\/s00330-015-4042-3","journal-title":"Eur Radiol"},{"key":"632_CR49","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jvir.2015.10.020","volume":"27","author":"W van den Bos","year":"2016","unstructured":"van den Bos\u00a0W, Scheffer\u00a0HJ, Vogel\u00a0JA et\u00a0al (2016) Thermal energy during irreversible electroporation and the influence of different ablation parameters. J\u00a0Vasc Interv Radiol 27:433\u2013443. https:\/\/doi.org\/10.1016\/j.jvir.2015.10.020","journal-title":"J Vasc Interv Radiol"},{"key":"632_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12885-016-2332-z","volume":"16","author":"MJ Scheltema","year":"2016","unstructured":"Scheltema\u00a0MJ, van den Bos\u00a0W, de Bruin\u00a0DM et al (2016) Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a\u00a0multi-center randomized controlled trial. BMC Cancer 16:299. https:\/\/doi.org\/10.1186\/s12885-016-2332-z","journal-title":"BMC Cancer"},{"key":"632_CR51","first-page":"337","volume":"69","author":"MJ Scheltema","year":"2016","unstructured":"Scheltema\u00a0MJ, van den Bos\u00a0W, Wagstaff\u00a0PG et\u00a0al (2016) Irreversible electroporation, a\u00a0new modality in Focal Therapy for prostate cancer. Arch Esp Urol 69:337\u2013344","journal-title":"Arch Esp Urol"},{"key":"632_CR52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ctrv.2018.10.004","volume":"70","author":"DLC Kee","year":"2018","unstructured":"Kee\u00a0DLC, Gal\u00a0J, Falk\u00a0AT et al (2018) Brachytherapy versus external beam radiotherapy boost for prostate cancer: systematic review with meta-analysis of randomized trials. Cancer Treat Rev 70:265\u2013271. https:\/\/doi.org\/10.1016\/j.ctrv.2018.10.004","journal-title":"Cancer Treat Rev"},{"key":"632_CR53","doi-asserted-by":"publisher","first-page":"403","DOI":"10.5114\/jcb.2017.70763","volume":"9","author":"GS Merrick","year":"2017","unstructured":"Merrick\u00a0GS, Tennant\u00a0A, Wallner\u00a0KE et\u00a0al (2017) Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: results of two prospective randomized trials. J\u00a0Contemp Brachytherapy 9:403\u2013409. https:\/\/doi.org\/10.5114\/jcb.2017.70763","journal-title":"J Contemp Brachytherapy"},{"key":"632_CR54","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.brachy.2016.11.005","volume":"16","author":"G Kovacs","year":"2017","unstructured":"Kovacs\u00a0G, Muller\u00a0K, Soror\u00a0T et al (2017) Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients. Brachytherapy 16:277\u2013281. https:\/\/doi.org\/10.1016\/j.brachy.2016.11.005","journal-title":"Brachytherapy"},{"key":"632_CR55","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ijrobp.2012.07.004","volume":"85","author":"N Zamboglou","year":"2013","unstructured":"Zamboglou\u00a0N, Tselis\u00a0N, Baltas\u00a0D et al (2013) High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 85:672\u2013678. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.07.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"632_CR56","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1748-717x-8-115","volume":"8","author":"N Tselis","year":"2013","unstructured":"Tselis\u00a0N, Tunn\u00a0UW, Chatzikonstantinou\u00a0G et al (2013) High dose rate brachytherapy as monotherapy for localised prostate cancer: a\u00a0hypofractionated two-implant approach in 351 consecutive patients. Radiat Oncol 8:115. https:\/\/doi.org\/10.1186\/1748-717x-8-115","journal-title":"Radiat Oncol"},{"key":"632_CR57","doi-asserted-by":"publisher","first-page":"495","DOI":"10.5114\/jcb.2018.81024","volume":"10","author":"TM Morgan","year":"2018","unstructured":"Morgan\u00a0TM, Press\u00a0RH, Cutrell\u00a0PK et al (2018) Brachytherapy for localized prostate cancer in the modern era: a\u00a0comparison of patient-reported quality of life outcomes among different techniques. J\u00a0Contemp Brachytherapy 10:495\u2013502. https:\/\/doi.org\/10.5114\/jcb.2018.81024","journal-title":"J Contemp Brachytherapy"},{"key":"632_CR58","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5114\/jcb.2018.76980","volume":"10","author":"TM Morgan","year":"2018","unstructured":"Morgan\u00a0TM, Press\u00a0RH, Cutrell\u00a0PK et\u00a0al (2018) Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes. J\u00a0Contemp Brachytherapy 10:211\u2013217. https:\/\/doi.org\/10.5114\/jcb.2018.76980","journal-title":"J Contemp Brachytherapy"},{"key":"632_CR59","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.brachy.2017.05.009","volume":"16","author":"V Srougi","year":"2017","unstructured":"Srougi\u00a0V, Barret\u00a0E, Nunes-Silva\u00a0I et al (2017) Focal brachytherapy for localized prostate cancer: Urinary toxicity depends on tumor location. Brachytherapy 16:988\u2013992. https:\/\/doi.org\/10.1016\/j.brachy.2017.05.009","journal-title":"Brachytherapy"},{"key":"632_CR60","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.eururo.2014.01.001","volume":"65","author":"W van den Bos","year":"2014","unstructured":"van den Bos\u00a0W, Muller\u00a0BG, Ahmed\u00a0H et\u00a0al (2014) Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol 65:1078\u20131083. https:\/\/doi.org\/10.1016\/j.eururo.2014.01.001","journal-title":"Eur Urol"},{"key":"632_CR61","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2012.11.057","volume":"63","author":"E Barret","year":"2013","unstructured":"Barret\u00a0E, Ahallal\u00a0Y, Sanchez-Salas\u00a0R et al (2013) Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 63:618\u2013622. https:\/\/doi.org\/10.1016\/j.eururo.2012.11.057","journal-title":"Eur Urol"},{"key":"632_CR62","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jncimonographs\/lgs041","volume":"2012","author":"TJ Wilt","year":"2012","unstructured":"Wilt\u00a0TJ (2012) The prostate cancer intervention versus observation trial: VA\/NCI\/AHRQ cooperative studies program #407 (PIVOT): design and baseline results of a\u00a0randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer. J\u00a0Natl Cancer Inst Monogr 2012:184\u2013190. https:\/\/doi.org\/10.1093\/jncimonographs\/lgs041","journal-title":"J Natl Cancer Inst Monogr"},{"key":"632_CR63","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1113162","volume":"367","author":"TJ Wilt","year":"2012","unstructured":"Wilt\u00a0TJ, Brawer\u00a0MK, Jones\u00a0KM et\u00a0al (2012) Radical prostatectomy versus observation for localized prostate cancer. N\u00a0Engl J Med 367:203\u2013213. https:\/\/doi.org\/10.1056\/NEJMoa1113162","journal-title":"N Engl J Med"},{"key":"632_CR64","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","volume":"379","author":"A Bill-Axelson","year":"2018","unstructured":"Bill-Axelson\u00a0A, Holmberg\u00a0L, Garmo\u00a0H et al (2018) Radical prostatectomy or watchful waiting in prostate cancer\u201429-year follow-up. N\u00a0Engl J Med 379:2319\u20132329. https:\/\/doi.org\/10.1056\/NEJMoa1807801","journal-title":"N Engl J Med"},{"key":"632_CR65","unstructured":"https:\/\/www.health.state.mn.us\/communities\/environment\/tracking\/docs\/cancerfandf.pdf"},{"key":"632_CR66","doi-asserted-by":"publisher","first-page":"509","DOI":"10.6004\/jnccn.2016.0060","volume":"14","author":"PR Carroll","year":"2016","unstructured":"Carroll\u00a0PR, Parsons\u00a0JK, Andriole\u00a0G et\u00a0al (2016) NCCN guidelines insights: prostate cancer early detection, version 2.2016. J\u00a0Natl Compr Canc Netw 14:509\u2013519","journal-title":"J Natl Compr Canc Netw"},{"key":"632_CR67","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00120-019-0921-6","volume":"58","author":"E Erne","year":"2019","unstructured":"Erne\u00a0E, Kaufmann\u00a0S, Nikolaou\u00a0K et\u00a0al (2019) Active surveillance in prostate cancer. Urologe\u00a0A 58:511\u2013517. https:\/\/doi.org\/10.1007\/s00120-019-0921-6","journal-title":"Urologe A"},{"key":"632_CR68","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.eururo.2015.12.015","volume":"69","author":"A Sivaraman","year":"2016","unstructured":"Sivaraman\u00a0A, Barret\u00a0E (2016) Focal therapy for prostate cancer: an \u201ca la carte\u201d approach. Eur Urol 69:973\u2013975. https:\/\/doi.org\/10.1016\/j.eururo.2015.12.015","journal-title":"Eur Urol"},{"key":"632_CR69","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.eururo.2010.03.034","volume":"58","author":"S Eggener","year":"2010","unstructured":"Eggener\u00a0S, Salomon\u00a0G, Scardino\u00a0PT et\u00a0al (2010) Focal therapy for prostate cancer: possibilities and limitations. Eur Urol 58:57\u201364. https:\/\/doi.org\/10.1016\/j.eururo.2010.03.034","journal-title":"Eur Urol"},{"key":"632_CR70","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.2967\/jnumed.118.221564","volume":"60","author":"IA Burger","year":"2019","unstructured":"Burger\u00a0IA, Muller\u00a0J, Donati\u00a0OF et al (2019) Ga-PSMA-11 PET\/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU. J\u00a0Nucl Med 60:1118\u20131123. https:\/\/doi.org\/10.2967\/jnumed.118.221564","journal-title":"J Nucl Med"},{"key":"632_CR71","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2019) Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.1, AWMF Registernummer: 043\/022OL, http:\/\/www.leitlinienprogramm-onkolo-gie.de\/leitlinien\/prostatakarzinom\/.  Accessed: 15 Aug 2019"}],"container-title":["Der Radiologe"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-019-00632-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00117-019-00632-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-019-00632-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T01:40:53Z","timestamp":1607650853000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00117-019-00632-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":71,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["632"],"URL":"https:\/\/doi.org\/10.1007\/s00117-019-00632-x","relation":{},"ISSN":["0033-832X","1432-2102"],"issn-type":[{"value":"0033-832X","type":"print"},{"value":"1432-2102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"12 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"A.\u00a0Kov\u00e1cs declares that he has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}